Abstract：Objective To study the features of blood lipid metabolic profile in overweight/obese boys aged 9-12 years and the possible mechanism of overweight/obesity in children. Methods According to body mass index (BMI), 72 boys, aged 9-12 years, were divided into a control group with 42 boys and an overweight/obesity group with 30 boys. Fasting venous blood samples were collected early in the morning. BMI, waist-hip ratio, body composition, and blood lipids were measured. Ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry technique was used to analyze the serum lipid compounds. A statistical analysis and visualization of the data were performed. Results Compared with the control group, the overweight/obesity group had significantly higher waist-hip ratio, body fat percentage, and triglyceride level (P < 0.05) and a significantly lower level of high-density lipoprotein cholesterol (P < 0.05). The metabolomic analysis identified 150 differentially expressed lipid compounds between the two groups, mainly glycerolipids (40.7%), glycerophospholipids (24.7%), fatty acyls (10.7%), and sphingolipids (7.3%). The levels of most of glycerolipids were significantly upregulated in the overweight/obesity group, while those of most of glycerophospholipids and sphingolipids were downregulated in this group. Key lipids with differential expression were enriched into two KEGG metabolic pathways, i.e., ether lipid metabolism pathway and terpenoid backbone biosynthesis pathway (P < 0.05), and might further affected the biosynthesis and metabolism of downstream coenzyme Q and other terpenoids (P=0.06). Conclusions Disordered lipid metabolic profile is observed in overweight/obese boys aged 9-12 years, with increases in most glycerolipids and reductions in glycerophospholipids and sphingolipids. Overweight/obese boys may have disorders in ether lipid metabolism and biosynthesis of terpenoid and even coenzyme Q.
UNICEF. The State of World's Children 2019[M]. New York:UNICEF, 2019:9-14.
[2]
Ward ZJ, Long MW, Resch SC, et al. Simulation of growth trajectories of childhood obesity into adulthood[J]. N Engl J Med, 2017, 377(22):2145-2153.
[3]
Simmonds M, Llewellyn A, Owen CG, et al. Predicting adult obesity from childhood obesity:a systematic review and meta-analysis[J]. Obes Rev, 2016, 17(2):95-107.
[4]
Anjos S, Feiteira E, Cerveira F, et al. Lipidomics reveals similar changes in serum phospholipid signatures of overweight and obese pediatric subjects[J]. J Proteome Res, 2019, 18(8):3174-3183.
Vu N, Narvaez-Rivas M, Chen GY, et al. Accurate mass and retention time library of serum lipids for type 1 diabetes research[J]. Anal Bioanal Chem, 2019, 411(23):5937-5949.
Gregg EW, Shaw JE. Global health effects of overweight and obesity[J]. N Engl J Med, 2017, 377(1):80-81.
[9]
Obesity:preventing, managing the global epidemic. Report of a WHO consultation[J]. World Health Organ Tech Rep Ser, 2000, 894:i-xii, 1-253.
[10]
O'Donnell VB, Ekroos K, Liebisch G, et al. Lipidomics:current state of the art in a fast moving field[J]. Wiley Interdiscip Rev Syst Biol Med, 2020, 12(1):e1466.
Nur Zati Iwani AK, Jalaludin MY, Wan Mohd Zin RM, et al. TG:HDL-C ratio is a good marker to identify children affected by obesity with increased cardiometabolic risk and insulin resistance[J]. Int J Endocrinol, 2019, 2019:8586167.
[14]
Cai Q, Huang H, Qian D, et al. 13-methyltetradecanoic acid exhibits anti-tumor activity on T-cell lymphomas in vitro and in vivo by down-regulating p-AKT and activating caspase-3[J]. PLoS One, 2013, 8(6):e65308.
[15]
Yu J, Yang LN, Wu YY, et al. 13-Methyltetradecanoic acid mitigates cerebral ischemia/reperfusion injury[J]. Neural Regen Res, 2016, 11(9):1431-1437.
[16]
Pakiet A, Wilczynski M, Rostkowska O, et al. The effect of one anastomosis gastric bypass on branched-chain fatty acid and branched-chain amino acid metabolism in subjects with morbid obesity[J]. Obes Surg, 2020, 30(1):304-312.
[17]
Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism[J]. Ann N Y Acad Sci, 2004, 1033:30-41.
[18]
Baci D, Bruno A, Bassani B, et al. Acetyl-l-carnitine is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways[J]. Cancer Lett, 2018, 429:100-116.
[19]
Cai J, Abramovici H, Gee SH, et al. Diacylglycerol kinases as sources of phosphatidic acid[J]. Biochim Biophys Acta, 2009, 1791(9):942-948.
[20]
Moradi H, Park C, Igarashi M, et al. Serum endocannabinoid levels in patients with end-stage renal disease[J]. J Endocr Soc, 2019, 3(10):1869-1880.
[21]
Breda M, Ricciardi G, Continenza MA. Histofunctional changes in the thyroid after administration of Benzedrine[J]. Boll Soc Ital Biol Sper, 1975, 51(18):1152-1157.
[22]
Thukkani AK, McHowat J, Hsu FF, et al. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions[J]. Circulation, 2003, 108(25):3128-3133.
[23]
Iqbal J, Walsh MT, Hammad SM, et al. Sphingolipids and lipoproteins in health and metabolic disorders[J]. Trends Endocrinol Metab, 2017, 28(7):506-518.
[24]
Hammad SM, Pierce JS, Soodavar F, et al. Blood sphingolipidomics in healthy humans:impact of sample collection methodology[J]. J Lipid Res, 2010, 51(10):3074-3087.
[25]
Choi S, Yoo YJ, Kim H, et al. Clinical and biochemical relevance of monounsaturated fatty acid metabolism targeting strategy for cancer stem cell elimination in colon cancer[J]. Biochem Biophys Res Commun, 2019, 519(1):100-105.
[26]
Kusumi A, Fujiwara TK, Tsunoyama TA, et al. Defining raft domains in the plasma membrane[J]. Traffic, 2020, 21(1):106-137.
[27]
Lu SM, Fairn GD. Mesoscale organization of domains in the plasma membrane-beyond the lipid raft[J]. Crit Rev Biochem Mol Biol, 2018, 53(2):192-207.
[28]
Zheng SJ, Qu F, Li JF, et al. Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection[J]. Int J Infect Dis, 2015, 33:149-155.
[29]
Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy[J]. Nat Rev Cancer, 2018, 18(1):33-50.
[30]
Lu Y, Li N, Gao L, et al. Acetylcarnitine is a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma[J]. Cancer Res, 2016, 76(10):2912-2920.
[31]
Miller BR, Kung Y. Structural features and domain movements controlling substrate binding and cofactor specificity in class II HMG-CoA reductase[J]. Biochemistry, 2018, 57(5):654-662.
